Phase Ⅱ Study of Dendritic and Cytokine-induced Killer Cells (DC-CIK) Treatment in Patients With Stage Ⅲ Colorectal Cancer
60 patients with stage Ⅲ CRC, who had received neoadjuvant and (or) adjuvant chemotherapy or
(and) radiotherapy according to NCCN guidelines, and got complete response (CR), will be
randomly divided into group A (receive DC-CIK treatment) or group B (just regularly follow
up), and the randomize ratio will be 1:1. Patients in group A will receive 2-3 cycles of
DC-CIK cells treatment (every 4 weeks). Patients in group B will have no anti-tumor therapy.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival (PFS)
5 years
No
China: Ministry of Health
CRC-01
NCT01839539
March 2013
March 2018
Name | Location |
---|